{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-024224","form_type":"8-K","ticker":"SHPH","cik":"0001757499","company_name":"Shuttle Pharmaceuticals Holdings, Inc.","filed_at":"2024-06-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.917227+00:00","generated_at":"2026-06-01T03:56:11.956699+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Shuttle Pharma names Timothy Lorber as CFO; Vander Hoek shifts to VP Regulatory","bullets":["Timothy Lorber, CPA with 40+ years experience, appointed CFO; part-time until Sept 9, 2024, then full-time from Sept 10, 2024.","Lorber receives $227k annual base salary; 227,635 RSUs vesting over 3 years; eligible for up to $72k milestone bonus.","Current CFO Michael Vander Hoek transitions to full-time Vice President, Regulatory concurrent with Lorber's full-time appointment.","Vander Hoek had served as both CFO and VP Regulatory for past four years; will now focus on regulatory matters for Phase 2 trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-024224","json":"https://secwatch.observer/filing/0001493152-24-024224.json","markdown":"https://secwatch.observer/filing/0001493152-24-024224.md","text":"https://secwatch.observer/filing/0001493152-24-024224.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1757499/000149315224024224/0001493152-24-024224-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1757499/000149315224024224/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T03:56:11.956699+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8fa0a96d9d","claim":"Timothy J. Lorber was appointed as Chief Financial Officer at Shuttle Pharmaceuticals Holdings, Inc..","evidence_excerpt":"On June 13, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an employment agreement (the “Employment Agreement”) with Mr. Timothy J. Lorber, CPA, 65, pursuant to which Mr. Lorber will serve as the Company’s part-time Chief Financial Officer until September 9, 2024 (the “Transition Period”) and, effective September 10, 2024, Mr. Lorber will assume the role of full-time Chief Financial Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315224024224/0001493152-24-024224-index.htm","confidence":0.95},{"claim_id":"9315dc2132","claim":"Michael Vander Hoek changed role as Vice President, Regulatory at Shuttle Pharmaceuticals Holdings, Inc..","evidence_excerpt":"The Company’s current Chief Financial Officer, Mr. Michael Vander Hoek, who also serves as our Vice President, Regulatory, will be transitioning out of his role as Chief Financial Officer and, effective September 10, 2024, will assume the Vice President, Regulatory position on a full-time basis.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315224024224/0001493152-24-024224-index.htm","confidence":0.95}],"comparable_filings":[{"accession":"0001628280-26-039461","ticker":"GRAL","company_name":"GRAIL, Inc.","filed_at":"2026-06-01T20:07:27+00:00","headline":"GRAIL appoints Joshua Ofman as CEO with amended compensation and severance","event_type":"leadership","sec_items":["5.02","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 8.01, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-039461","json":"https://secwatch.observer/filing/0001628280-26-039461.json","markdown":"https://secwatch.observer/filing/0001628280-26-039461.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1699031/000162828026039461/0001628280-26-039461-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1699031/000162828026039461/gral-20260601.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On June 13, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an employment agreement (the “Employment Agreement”) with Mr. Timothy J. Lorber, CPA, 65, pursuant to which Mr. Lorber will serve as the Company’s part-time Chief Financial Officer until September 9, 2024 (the “Transition Period”) and, effective September 10, 2024, Mr. Lorber will assume the role of full-time Chief Financial Officer of the Company.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315224024224/0001493152-24-024224-index.htm","comparable_excerpt":"Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers In connection with Dr. Joshua Ofman’s appointment as the Chief Executive Officer of GRAIL, Inc. (the “Company”), on June 1, 2026, the Company’s board of directors (the “Board”) approved an amended and restated offer letter (the “Amended Offer Letter”) and authorized and directed the Company to enter into such Amended Offer Letter with Dr. Ofman, with the Amended Offer Letter effective as of June 1, 2026 (the “Effective Date”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1699031/000162828026039461/0001628280-26-039461-index.htm"}},{"accession":"0001515156-26-000069","ticker":"ARQ","company_name":"Arq, Inc.","filed_at":"2026-05-27T20:32:10+00:00","headline":"Arq appoints Shimon Steinmetz as CFO, CAO Stacia Hansen resigns","event_type":"leadership","sec_items":["5.02","8.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 8.01, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001515156-26-000069","json":"https://secwatch.observer/filing/0001515156-26-000069.json","markdown":"https://secwatch.observer/filing/0001515156-26-000069.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1515156/000151515626000069/0001515156-26-000069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1515156/000151515626000069/ades-20260520.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On June 13, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an employment agreement (the “Employment Agreement”) with Mr. Timothy J. Lorber, CPA, 65, pursuant to which Mr. Lorber will serve as the Company’s part-time Chief Financial Officer until September 9, 2024 (the “Transition Period”) and, effective September 10, 2024, Mr. Lorber will assume the role of full-time Chief Financial Officer of the Company.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315224024224/0001493152-24-024224-index.htm","comparable_excerpt":"On May 20, 2026, Stacia Hansen, the Chief Accounting Officer and Treasurer of the Company, submitted her resignation and the Board accepted such resignation. The effective date of Ms. Hansen's resignation as Chief Accounting Officer is expected to be June 12, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1515156/000151515626000069/0001515156-26-000069-index.htm"}},{"accession":"0001193125-26-251709","ticker":"CRVL","company_name":"CORVEL CORP","filed_at":"2026-06-01T21:05:42+00:00","headline":"CorVel CEO Michael Combs to become Executive Chair; Sarah Scott appointed CEO and President effective July 1, 2026","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251709","json":"https://secwatch.observer/filing/0001193125-26-251709.json","markdown":"https://secwatch.observer/filing/0001193125-26-251709.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/874866/000119312526251709/0001193125-26-251709-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874866/000119312526251709/d24231d8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On June 13, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an employment agreement (the “Employment Agreement”) with Mr. Timothy J. Lorber, CPA, 65, pursuant to which Mr. Lorber will serve as the Company’s part-time Chief Financial Officer until September 9, 2024 (the “Transition Period”) and, effective September 10, 2024, Mr. Lorber will assume the role of full-time Chief Financial Officer of the Company.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315224024224/0001493152-24-024224-index.htm","comparable_excerpt":"In connection with the leadership transition, the Board appointed Sarah Scott to serve as Chief Executive Officer and President of the Company, effective July 1, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/874866/000119312526251709/0001193125-26-251709-index.htm"}},{"accession":"0001140361-26-023584","ticker":"WTTR","company_name":"Select Water Solutions, Inc.","filed_at":"2026-06-01T21:00:50+00:00","headline":"Select Water Solutions COO Skarke moves to Chief Commercial Officer; no successor named","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-023584","json":"https://secwatch.observer/filing/0001140361-26-023584.json","markdown":"https://secwatch.observer/filing/0001140361-26-023584.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1693256/000114036126023584/0001140361-26-023584-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1693256/000114036126023584/ef20075332_8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On June 13, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an employment agreement (the “Employment Agreement”) with Mr. Timothy J. Lorber, CPA, 65, pursuant to which Mr. Lorber will serve as the Company’s part-time Chief Financial Officer until September 9, 2024 (the “Transition Period”) and, effective September 10, 2024, Mr. Lorber will assume the role of full-time Chief Financial Officer of the Company.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315224024224/0001493152-24-024224-index.htm","comparable_excerpt":"Effective June 1, 2026, Michael C. Skarke transitioned from serving as the Executive Vice President and Chief Operating Officer of Select Water Solutions, Inc. (the “Company”) to serving as the Company’s Executive Vice President and Chief Commercial Officer,","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1693256/000114036126023584/0001140361-26-023584-index.htm"}},{"accession":"0001671933-26-000063","ticker":"TTD","company_name":"Trade Desk, Inc.","filed_at":"2026-06-01T20:35:28+00:00","headline":"The Trade Desk appoints Nate Olmstead as CFO effective July 9, 2026; interim CFO Davis resumes CAO role","event_type":"leadership","sec_items":["5.02","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001671933-26-000063","json":"https://secwatch.observer/filing/0001671933-26-000063.json","markdown":"https://secwatch.observer/filing/0001671933-26-000063.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671933/000167193326000063/0001671933-26-000063-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671933/000167193326000063/ttd-20260601.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On June 13, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an employment agreement (the “Employment Agreement”) with Mr. Timothy J. Lorber, CPA, 65, pursuant to which Mr. Lorber will serve as the Company’s part-time Chief Financial Officer until September 9, 2024 (the “Transition Period”) and, effective September 10, 2024, Mr. Lorber will assume the role of full-time Chief Financial Officer of the Company.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315224024224/0001493152-24-024224-index.htm","comparable_excerpt":"On June 1, 2026, The Trade Desk, Inc. (the “Company”) announced the appointment of Nate Olmstead, age 54, as the Company’s chief financial officer.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1671933/000167193326000063/0001671933-26-000063-index.htm"}},{"accession":"0000105770-26-000080","ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2026-06-01T20:32:30+00:00","headline":"West Pharmaceutical appoints Michel Lagarde as CEO; Green retires, Friel becomes Chair","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000105770-26-000080","json":"https://secwatch.observer/filing/0000105770-26-000080.json","markdown":"https://secwatch.observer/filing/0000105770-26-000080.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000080/0000105770-26-000080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000080/wst-20260531.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On June 13, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an employment agreement (the “Employment Agreement”) with Mr. Timothy J. Lorber, CPA, 65, pursuant to which Mr. Lorber will serve as the Company’s part-time Chief Financial Officer until September 9, 2024 (the “Transition Period”) and, effective September 10, 2024, Mr. Lorber will assume the role of full-time Chief Financial Officer of the Company.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315224024224/0001493152-24-024224-index.htm","comparable_excerpt":"As of the Start Date, Mr. Green will resign as a member of the Board and Mr. Lagarde will be appointed as a member of the Board to fill that vacancy.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000080/0000105770-26-000080-index.htm"}},{"accession":"0000060519-26-000024","ticker":"LPX","company_name":"LOUISIANA-PACIFIC CORP","filed_at":"2026-06-01T20:31:12+00:00","headline":"LP Building Solutions announces CFO succession: Alan Haughie to retire; Aaron Howald named CFO effective Sept 1, 2026","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0000060519-26-000024","json":"https://secwatch.observer/filing/0000060519-26-000024.json","markdown":"https://secwatch.observer/filing/0000060519-26-000024.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/60519/000006051926000024/0000060519-26-000024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/60519/000006051926000024/lpx-20260527.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On June 13, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an employment agreement (the “Employment Agreement”) with Mr. Timothy J. Lorber, CPA, 65, pursuant to which Mr. Lorber will serve as the Company’s part-time Chief Financial Officer until September 9, 2024 (the “Transition Period”) and, effective September 10, 2024, Mr. Lorber will assume the role of full-time Chief Financial Officer of the Company.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315224024224/0001493152-24-024224-index.htm","comparable_excerpt":"On May 27, 2026, Alan J.M. Haughie, Executive Vice President and Chief Financial Officer of Louisiana-Pacific Corporation (“LP”, the “Company”), notified the Board of Directors of LP (the “Board”) of his intention to retire from the role of Executive Vice President and Chief Financial Officer, effective September 1, 2026.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/60519/000006051926000024/0000060519-26-000024-index.htm"}},{"accession":"0001193125-26-251467","ticker":"PENG","company_name":"Penguin Solutions, Inc.","filed_at":"2026-06-01T20:17:28+00:00","headline":"Penguin Solutions CFO Nate Olmstead to step down; Aaron Johnson named interim CFO; reaffirms FY2026 guidance at high end","event_type":"leadership","sec_items":["5.02","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: executive_change","same SEC item: 5.02, 9.01","same event type: leadership","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251467","json":"https://secwatch.observer/filing/0001193125-26-251467.json","markdown":"https://secwatch.observer/filing/0001193125-26-251467.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1616533/000119312526251467/0001193125-26-251467-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1616533/000119312526251467/d104493d8k.htm"},"side_by_side_evidence":{"fact_type":"executive_change","source_excerpt":"On June 13, 2024, Shuttle Pharmaceuticals Holdings, Inc., a Delaware corporation (the “Company”), entered into an employment agreement (the “Employment Agreement”) with Mr. Timothy J. Lorber, CPA, 65, pursuant to which Mr. Lorber will serve as the Company’s part-time Chief Financial Officer until September 9, 2024 (the “Transition Period”) and, effective September 10, 2024, Mr. Lorber will assume the role of full-time Chief Financial Officer of the Company.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1757499/000149315224024224/0001493152-24-024224-index.htm","comparable_excerpt":"On May 31, 2026, the board of directors of the Company appointed Aaron Johnson, the Company’s Vice President, Finance and Accounting, as interim CFO and as the Company’s principal financial and accounting officer, succeeding Mr. Olmstead in these positions effective as of July 9, 2026, on an interim basis until the Company appoints a successor.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1616533/000119312526251467/0001193125-26-251467-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}